Comparative Pharmacology
Head-to-head clinical analysis: DEMULEN 1 35 21 versus SIMLIYA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DEMULEN 1 35 21 versus SIMLIYA.
DEMULEN 1/35-21 vs SIMLIYA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Combination oral contraceptive containing ethinyl estradiol (estrogen) and ethynodiol diacetate (progestin). Inhibits gonadotropin secretion (FSH, LH) via negative feedback on hypothalamic-pituitary axis, suppressing ovulation. Additionally, thickens cervical mucus and alters endometrial receptivity.
Not available; SIMLIYA is a trademarked combination drug with no established mechanism of action.
One tablet orally once daily for 21 days, followed by 7 days off. Each tablet contains 1 mg ethynodiol diacetate and 35 mcg ethinyl estradiol.
Insulin glargine (SIMLIYA) is a long-acting insulin analog administered subcutaneously once daily. Typical starting dose for adults with type 2 diabetes is 0.2 units/kg or 10 units once daily, adjusted based on blood glucose targets. For type 1 diabetes, total daily dose is divided; basal insulin glargine typically constitutes 40-50% of total daily dose, given once daily.
None Documented
None Documented
Ethinyl estradiol: 13±3 hours (terminal); norethindrone: 8±3 hours. Steady-state achieved after ~5 days.
Terminal elimination half-life is approximately 12 hours; clinically, steady state is achieved within 2-3 days of regular dosing.
Renal (primarily as glucuronide and sulfate conjugates): ~60%; fecal: ~40%
Renal excretion of unchanged drug accounts for ~70% of elimination; biliary/fecal excretion accounts for ~25%, with the remainder as metabolites.
Category C
Category C
Oral Contraceptive
Oral Contraceptive